Krishnansu S. Tewari
California gynaecologic oncologist who led GOG 240, the trial that made bevacizumab the first targeted drug to lengthen survival in advanced cervical cancer, and EMPOWER-Cervical 1, which did the same for the PD-1 antibody cemiplimab.
Overview
Krishnansu Tewari is a gynaecologic oncologist at the University of California, Irvine. He was first author of the 2014 New England Journal of Medicine report of GOG 240, in which adding bevacizumab to chemotherapy improved overall survival in recurrent, persistent or metastatic cervical cancer, and of the 2022 New England Journal of Medicine report of EMPOWER-Cervical 1, in which cemiplimab lengthened survival compared with chemotherapy after platinum failure.
Cemiplimab is an option for second-line cervical cancer in patients who have not had immunotherapy, though most now receive pembrolizumab first line, moving cemiplimab later or out of sequence.
Platinum-paclitaxel with bevacizumab became the first-line standard for advanced cervical cancer and remains the backbone to which pembrolizumab is added.
Similar pages
not linked directly; found by shared links- TrialEMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9
Shares EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum, Recurrent or metastatic cervical cancer, Cervical cancer.
- PersonAmanda Nickles Fader
Shares the tags gynaecological, trialist.
- PersonDavid M. Gershenson
Shares the tags gynaecological, trialist.
- PersonShannon N. Westin
Shares the tags gynaecological, trialist.
- PersonAna Oaknin
Shares Cervical cancer and the tags gynaecological, trialist.
- PersonMarie Plante
Shares Cervical cancer and the tags cervical, trialist.
- PersonSusana Banerjee
Shares the tags gynaecological, trialist.
- PersonVicky Makker
Shares the tags gynaecological, trialist.